1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Germany >
  5. VolitionRx Acquires Octamer

M&A Deal Summary

VolitionRx Acquires Octamer

On December 16, 2019, VolitionRx acquired life science company Octamer

Acquisition Highlights
  • This is VolitionRx’s 1st transaction in the Life Science sector.
  • This is VolitionRx’s 1st transaction in Germany.

M&A Deal Summary
Date 2019-12-16
Target Octamer
Sector Life Science
Buyer(s) VolitionRx
Deal Type Add-on Acquisition

Target

Octamer

Gräfelfing, Germany
Octamer GmbH develops and distributes epigenetic reagents. Octamer GmbH strives to provide the best epigenetic screening and research reagents. Defined nucleosomes, with colorful fluorescent tags and defined DNA sequences that make your epigenetic assay unique.

Search 215,074 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

VolitionRx

Henderson, Nevada, United States
Category Company
Sector Life Science
Employees85
Revenue 1M USD (2024)
DESCRIPTION

VolitionRx is a life sciences company focused on developing diagnostic tests for cancer and other conditions. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid an indication that disease is present. VolitionRx is based in Henderson, Nevada.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: Germany M&A 1 of 1
Year: 2019 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal